Self-management is safe and reliable in patients with long-term oral anticoagulation(OAC). However, no study has yetassessed the safety and efficacy of OAC self-managementi ne lderly patients withm ajor thromboembolic andh aemorrhagicc omplications as primaryoutcomes.Inthis multi-centre, open, randomisedcontrolledtrial, patients aged 60 years or morewererandomisedinto the self-managementgroup (SMG) (N=99) or routine care group (RCG) (N=96).We describe the rationale,design,baseline characteristics and interim analyseso fo ral anticoagulation control quality withinthe first year of follow-up.The medianso ft he squared internationaln ormalisedr atio (INR) value deviations aftersix and 12 months were significantlylower Keywords Oral anticoagulation, self-management,e lderly patients,r andomized controlledtrial in the SMG with medians of 0.16 and 0.16 compared to the RCG with medians of 0.25 and 0.25.Thepercentage of time withintargetrange and thepercentage of INRmeasurements within targetrange were significantlyhigher in the SMG versus theRCG within the first six months (medians 71% vs.58% and 69% vs. 57%), and during the second sixm onths of thes tudy (75%v s. 67% and 72% vs.5 7%). Then umbers of allt hromboembolic events requiring hospitalisation, major bleeding events, and deathsw eres imilari nb oth groups. Thesep reliminary results suggestthat self-managementoforal anticoagulation is safeand feasiblefor elderlypatientswilling to participateinastructured trainingprogramme.
Introduction
Oral anticoagulation (OAC)has been shown to be highlyeffective in preventing thromboembolic complications in patients for whom it is indicated (1, 2) . Numerous studies have documented that elderlypatients seem to benefitmost from OACtherapy (1, 3, 4) . Atrialfibrillation (AF), the incidenceofw hich increases with age and approaches 10% for individuals aged ≥ 80 years, carries the main risk for stroke (5) ; and among elderlypatients without antithrombotic therapy, AF-related strokeisassociated witha30-daymortality of 24%. In contrast, only6%ofpatients on warfarin at the time of strokeand with an international normalisedratio (INR)of2.0 or greater,diedwithin 30 days (6).
Despiteits proven benefit, numerousstudies have reportedreluctance in prescribingOAC due to avarietyofbarriers,especially in the elderly (7) (8) (9) (10) . Risk of haemorrhage,whichisinfact twice as great in thoseover70yearsofage as in youngerpatients, is one of the major determinants of refusal to prescribe OACt herapy (11, 12) .The riskofstroke rises steeply in patients with atrial fibrillation when INRvalues arelower than 1.8 (13) , andINR values greater than 4to5are rapidlyassociated withincreased bleedingrates (14, 15) . Duetorelativelysmall therapeutic ranges,inreality often only asmall percentage of the INR values have been found to be within the target range, which canbelow as 29% of INRmeasurements, as seen in routine carepatients prior to participation in arandomised self-management programmestudy (16) .
One wayt oi mproveO AC care is by introducing patients' self-management of OACtherapy. In this context it is important to differentiate between INR self-testing alone, and full selfmanagement. Self-management includess elf-adaptation of the anticoagulation treatment basedonself-monitoring results after the patients have participated in as tructured instruction and treatment programme. Asystematic reviewofrandomisedcontrolled trials has shown that the anticoagulation status of selfmanaged patients is better than or at least equivalent to thatofpatients monitored by specialiseda nticoagulation clinics or general practitioners (17) ,and in arecently published meta-analysis, the thromboembolic event and deathrates were significantly reduced (18)inpatients with self-management.Astudy by Beyth et al. (19) involving elderly patients showedthat excessive bleeding rates can be successfully reduced under self-monitoring. To date,therehavebeen no randomisedtrials to evaluate the longterm effectso fs elf-management of OACi nt he elderlyp opulation.
Our study aims to provide answers to this important medical question by examining elderly patients receiving long-termanticoagulation treatment and randomised into self-management versusr outine-careg roups,w ith thromboembolic and haemorrhagic complications as primaryoutcomes. In this publication we describe the rationale, design, baseline characteristics and interim analysesofO AC control after the first year of follow-up. Thefinalpaper with the analysis of the primary end-pointswill be publishedafter conclusion of the studyonFebruary28, 2007.
Methods

Participants
Four departments specializing in the treatment of patients receiving long-termO AC therapyi nitiallyj oined this multi-centre study,which wasapprovedb ythe ethics committeesofall participating centres. OnApril 26, 2006 , one centre wase xcluded after an external expertopinion (personalcommunication) drew attention to the largeamountofdatamissing in the follow-up examinations.Ofthe 21 randomised patients in that centre,atleast half did not come for the first follow-up visit, and increasing numbers failedtoappearfor subsequent visits. According to the external review,nobiascan be expected because randomisation wasperformed within each participating centre, and the exclusion from analyses occurred beforeany calculations were made. Data on these 21 patients from theexcludedcentre will therefore no longer be consideredinthis publication.
All consecutive patients on long-terma nticoagulation (n=458) presenting at the participating centresw ere screened and,i fe ligible and willing to participate,w ere includedi nt he study.Inclusion criteria were indication for long-termanticoagulation either with phenprocoumon or acenocoumarol and age ≥ 60 years.P atients were alsoe ligible for participation if longterm anticoagulation wasr ecently indicated and theyh ad not beenonOAC treatment before. Exclusion criteria were previous participation in as elf-management OACp rogramme,s evere cognitive (assessed informallyb ys tudy personnel) or terminal illness. Thepatient wasinformed by the physicianofhis/herindividuallydefinedINR therapeutic target range.
The recruitment phase started in March 2002.D ue to the slowr ecruitment rate, the recruitment phase wase xtendedf or one additional year and closed in February2005. The study will end on February28, 2007, twoyears after the randomisation of the last patient. Thefollow-up timewill rangefrom twotofive years.
Procedures
Patients were block-randomised by centre according to acomputer-based system to either the self-management group (SMG) or the routine-care group (RCG). Allocation wasdone by acentral statistical office by faxa nd without awarenesso fs ubject data.The sequence of randomisation wasconcealeduntil the patient wasassignedtoagroup.
Allphysicianand nurse instructorsinvolved in the patients' training programme participatedinatwo-daytraining courseas developedbySawicki et al. (16) , whichwas adaptedand modified forthe needs of elderlypatients. Thegoals of the oralanticoagulation training and self-management programme were to help patients in assuming increased responsibility for disease management basedonsystematic INRvalue self-monitoring and adjustment of the anticoagulant dosage. In addition, instructors were trained in additionalt eaching skills forw orking with elderlypatients.
Patients assignedtothe RCGparticipatedinasingle 90-minute session includingbasic theoretical information on haemostasis, main characteristics of oral anticoagulants, potentialrisks for thromboembolism and bleeding,and problems that might be encounteredinspecial situations such as exercise,traveland diet changes. During the whole study period,theywere advisedwith regard to changes in the anticoagulant dosage by their usual attendingp hysicians, eitheri ng eneral practiceo ra tahospitalbasedspecialised anticoagulation clinic.
In the SMG,patients participatedinfour consecutive weekly instruction sessions of 90 to 120 minuteseach,ingroups of three to sixpatients.During the firsts ession, patients were informed about anticoagulation in generaland receivedextensivetraining in INRs elf-monitoring using the whole blood PT/INRm onitor CoaguChek ® S( Roche Diagnostics GmbH, Mannheim,G ermany),whichhas been previouslyvalidated (20) . During the first week,patients were encouragedtomeasure INR values routinely andt or ecord the results and the anticoagulant dosagesi nt heir diaries.The second session includedi nstructions on preventing bleedingand thromboembolic complications andprovided more detailed information on haemostasis. During the third session, patients were instructed about indications andmodels for reducing or increasingthe anticoagulant dosages to achieve INRvalues within the target range. Severalexamples of adapting drug dosage were discussed, andt he patients completed practical exercises.Inthe last session, patients were informedabout problems thatm ightd evelopw ith operations,i llness, exercise, travel and additionalm edications,a nd keyi nformation from the training programmes wasrecapitulated. At the beginning of the second to the fourth sessions,t he quality of INR self-monitoringw as checked by the nursei nstructor.Afterp articipation in the programme, thepatients hadtoestimate their INRvaluewith an absolute deviation of lessthan0.4 from the referencevalue. If this wasnot the case, thetraining course hadtoberepeated.Afterpar-ticipation in the structuredp rogramme, thep atients were given their diaries and encouraged to control their INRvalues by selfmonitoring once aweek,toadjust their anticoagulant dosageaccordingly, andtocontact thetraining centreincaseofdifficulties.
Follow-up visits were scheduledu pon screening and after randomisation for participation in the training courses, either once or four times in the RCGorthe SMG, respectively,and then everysix months. At baseline and at each follow-up visit, there wasaclinical examination, and patients were questionedabout minor or major bleeding or thromboembolic events, anyinterim illnesses, changes in long-termm edications,a nd hospitalisations. Anticoagulation status wasassessedb ypatient records in the diaries expressed as INRv alues;acopyo ft he patient's diarywas made at each visit. (18) 15% (14) Pulmonary embolism 0 6% (6) 16% (15) Other 0 7% (7) 11% (11) Intended INRtarget range 0 .148 2-3 81% (80) 82% (79) 2.5-3.5 18% (18) 12% (12) Other 0 1% (1) 0 5% (5) Duration of oralanticoagulationtreatment, years 0 5.5 ±7.0 0 5. The reason for using onlyp atients' diary reportsi st hat the laboratorytests differ among each other (24) . In both the SMG (CoaguChek selfmeasurement)and in the RCG(measurement at the attendingphysician'sofficeoratahospital-basedspecialised anticoagulation clinic with its owni n-house device), the INRvalues were always measuredwith one and the same laboratorys ystem, whichp resents the valuesa ccording to the anticoagulant dosage adjustments made.
Fort he interim analysesp resentedi nt his paper, one year after randomisation of the last patient, the primary outcome was the efficacyoforal anticoagulation control reported as the median squaredINR value deviation 
Samplesizeand statistical analysis
Basedonpreviouslypublished pilot studies (16, 25) , the calculation of sample size requiredw as based on the followinga ssumptions. To detect a50% reduction in thromboembolic events and major bleedingsbetween the twotreatment groups assuming asignificance levelofp=0.05 and apower of 90%, asamplesize of 88 patients per group wasneeded.With acalculated dropout rate of 10%, this calculation resultedinatotal of 200 patients.
Forc ontinuous variables, differences were assessed by the Wilcoxon test, unpaired for between-group comparisons and paired for within-group comparisons. Categorical data were compared by Chi 2 -tests. Forthe time-to-event analyses, Kaplan Meier curveswill be presented,and the log-rank test will be performed. Significance levelwas setatp=0.05. Medians were used becauseofthe skewed distributions of the data. Forthe interim analysis presented here, statisticswere done using the Rpackage for statistical computing (26) , an open-source implementation of the S-Plus software package.
Results
In all,458 consecutive patients from the threeevaluatedcentres were assessed for eligibility; 263 were excluded forthe reasons describedinthe trial profile in Figure 1 .
Of the 195 patients whow ere randomised, 99 patients were randomisedt ot he SMGa nd 96 patients to the RCG. Table1 shows the baseline characteristics forb oth groups. No statisticallysignificant differences were observedinthe distribution of the baseline variablesage, genderand intended INRranges. Clinical indications for OACwere atrial fibrillation, mechanical prosthetic heart valve, venous thromboembolism,pulmonaryartery disease and otherssuch as recurrent stroke, myocardialinfarction,a rterial embolism, ischemic and dilatedc ardiomyopathy, coronarya rteryb ypass graft,p eripheral arterial and venous bypass graft,polycythemia vera rubra and thrombophlebitis,and ventricular aneurysm. At baseline therewere no significant differences between the groups in terms of co-morbidities, previous thromboembolic and haemorrhagic complications and other long-termmedications.Ninety-one percent and 89%ofpa-tients were on phenprocoumon and 9% and 11%were on acenocoumarol in the SMG and RCG,respectively.
At baseline, thegroups differed significantlywith regard to the therapeutic INR control obtainedf rom the patients' diaries during the year previous to randomisation. Them edian of the squared INR value deviation wass ignificantly higher in the SMG, accompanied by asignificantly lowermedian percentage of time within the target range and amedian percentage of INR measurementsw ithin the target range in this group. This fact goes togetherwith asignificantly higher percentage of patients in the SMGwith INR valuesbelow the therapeutic rangeinterms of time and measurementsatbaseline as compared to the RCG.
Of 99 patients randomisedtothe SMG, 90 attendedand successfullyc ompleted training. Of the patients whoc ompleted training, 96% completedthe first year of follow-up in the SMG. Only twop atients could not manage routine self-measurement and twoo therp atients were reluctantt op erform self-management after the course. Twopatients hadmanual impairment; one patient hadah istoryo fs trokea nd anotherp atient hadP arkinson's syndrome;both patients were nonetheless includedinthe study,and measurements were performed by relatives.The dropout rate in the RCGw as 6%,a nd eight control-group patients beganw ith self-management sixm onths after the study began (Fig. 1) .
The median frequencyofINR measurementsper patient in the SMG was27and 24 comparedtoeight and seveninthe RCG after the first and second six-month periods, respectively.The medians of the squared INRv alue deviations after six and 12 monthsw ere significantlyl ower in the SMG with medians of Data median (interquartile range -25and 75 percentile) or %(n). * Reasons formissing data at baseline:Inthe SMG,three patients started with OACtreatmentatrandomisation, three patients lost their patient diaries, one patient withdrew informedconsent due to distance to study centrebeforeproviding patient diaryand has missing data forall follow-up examinations. In the RCG one patient died immediately after randomisation and beforeproviding patient's diary and has missing data forall follow-up visits. ** Reasons formissing data at sixmonths' follow-up arereported in the flow chart. *** Reasons formissing data at 12 months'follow-up arereported in the flow chart. (Table 2) . During the first sixmonths, the percentage of timewithin target range and the percentage of INRmeasurementswithin target range were significantly higher in the SMGversus the RCG with medians 71% versus5 8% and 69% versus5 7%, respectively. During thesecondsix monthsofthe study,these differencesremainedstatistically significant with mediansof75% versus67% and 72% versus5 7% for the percentage of timew ithin target range and the percentage of INR measurementsfor self-management comparedwith routine management. Aftersix monthsof treatment, as ignificantly higher proportion of patients was above the target range in the RCG group with respecttotime and measurements. During the secondsix months, onlythe percentage of INRm easurementsa bove the target range wass ignificantly higher in the RCG.
In addition, we found as ignificant within-group improvement in the mediano ft he squared INRv alue deviations (p<0.001), the percentage of time (p<0.001)and the numbersof INR readings( p<0.001) within the target range betweenp restudyand the first year of follow-up in the SMG. Overall, efficacyinO AC control remained unchanged in the RCG.
Forty-nine patients in the RCGwere treated in general practices and 47 patients at hospital-baseds pecialised anticoagulation clinics. At baseline, OACc ontrol did not differs ignificantly betweenthe SMGand the generalpractice-treated RCG. During thefirst year of treatment, the medianofthe squared INR value deviation wassignificantly reduced in the SMG versusthe generalpractice-treated RCG,with medians of 0.16versus 0.27; p<0.001. The percentage of timew ithin target range (median, 74%v s. 58%;p <0.001) and the percentage of INRm easurements (median, 70%vs. 50%;p<0.001) also improvedsignificantly in the SMG versusthe generalpractice-treated RCG.Concentrating on the RCGtreated in hospital-basedspecialised anticoagulation clinics, the OACquality wassignificantly higher at baseline and remained stable over the first year of treatment. For the interimanalysis after one year of treatment, there wasnosignificant difference in termsofpercentage of time within target range between the SMG and the hospital-basedspecialised anticoagulation clinic RCG(median, 74% vs. 71%,p=0.082). However,the median of the squared INRvalue deviation wassignificantly reduced in the SMG versusthe hospital-basedspecialised anticoagulation clinic RCGw ith medians of 0.16v ersus 0.24 (p=0.028), and the percentage of INR measurementswithin target range improvedsignificantly as well (median, 70%vs. 60%, p=0.005).
The numbersofall thromboembolic eventsrequiring hospitalisations,major bleeding events, and deaths throughthe end of the first studyyear didnot differbetween the groups and arereported forall randomisedpatients in Table3.
Discussion
This randomised controlled trial willprimarily attempt to determine whether thromboembolic eventsrequiring hospitalisation and major bleeding complications can be reduced by self-management of oral anticoagulation in patients over 60 years of age. As long-termd ataf rom studiesw ith elderly self-management patients (self-testing and self-dosing after participation in a structuredtreatment programme)are rare, we expectthat the results in the final publication with the "analysis of morbidityand mortality end-points"w ill have important implications for the treatment of elderly patients in the future.Todate, only one randomised trial including patients with amean age of 64 to 67 has shown asignificant reduction in thromboembolic complications (27), and oneotherstudy indicated thatexcessive bleeding rates can be successfullyreduced when elderly patients performselftesting (19) . However, though clear evidenceofthe superiority of self-management treatment for elderlypatients is still lacking,it is known from arecently published meta-analysis combining all presentlya vailabler andomisedt rials with predominantly younger patients and shortfollow-up times that thromboembolic complications and death rates canb es ignificantly reduced in self-managed patients (18) .
Overall,43% of eligible patients whowere invitedbydoctors to participate at the studycentres were randomised; this is comparable to aSpanish study (27) and astudy performedonelderly patients in the United Kingdom (28) butismuch higher than in the studies presentedrecently by Gadisseur et al. and Fitzmaurice et al. (29, 30) with about 25%.
Of those patients whowere randomisedtoself-management, 91% completedtraining, and 96%ofthose whostarted self-management completed the first 12 monthsoffollow-up. Such alow dropout rate wasonlyfound in the study by Khan et al. (28) and is very lowc ompared to other randomised controlled trials including ah igh proportion of elderly patients assigned to selfmanagement with ar angeo f2 1% to 28% (19, 27, 29) . Some other studies presentedc omparably lowd ropoutr ates (16, 30) butincludedmuch younger patients. The withdrawalrateinthe RCGw as 6%,a nd eight patients in the this group started with self-management six months after the study began (Fig. 1) .
After one year of intervention, patient self-management of oral anticoagulation wassuperior to routine care in terms of the median squareINR deviation, whichwas the predefinedprimary outcome for this analysis. This parameterprovides useful information on the evaluation of positive and negative differencesbetween the INR target range and INR values, as it simultaneously incorporates very high and very lowINR values. This result is supportedb ythe significant improvement of the percentage of timeand readings within the therapeutic range for INRbetween the twogroups after sixand 12 months of treatment. Patients in the SMG hadp oorera nticoagulation control at baseline, butefficacywas markedlyimproved after the first year of treatment. Apossible explanation could be that after completing the structured training programme,patients under self-management can bettera djust the anticoagulant dosage whenever necessary thancan the physicianinthe setting of routine care.In general, therapeutic INRcontrol in the SMGw as good and almost comparable to otherrandomisedtrials (18, 31) .
In the RCG, the accuracyofOAC control did not change over the observation time of one year even though the patients had also undergone abasic training course. Thefact thatthe percentage of timea nd of INRv alues within the target range didn ot change over time might be becausethe number of INRmeasurements wasessentiallylow and stable during the first year of follow-up (on the average, about onemeasurement per month). This mayindicate that monthlymonitoring, as currentlyforeseenfor routine care in Germanya nd Austria, does not suffice fort he prompt modifications of the dailydose that would be needed to optimize the INRlevels. This is in contrasttothe small study of Khanetal. (28) , where elderly patients in the education and clinicalc are group whop articipatedi nat wo-hour training session hadaclear improvement in time within the therapeutic rangeat the end of the study. This publication does not,however,clearly state howoften INR wasmeasured and whether the dosage was subsequentlya dapted. Another interesting randomised trial reported on aRCG thatcompleted threetraining sessions (30) . It showedthat the efficacyofOAC improved fromthe beginning to the end of the study and did not differbetween twoothergroups on weeklyself-management or weeklyself-testing only.
Patients in the RCG were advisedbydoctorseitheringeneral practiceoratahospital-basedspecialised anticoagulation clinic. The resultso fo ur analysis indicatet hat patients treateda t specialisedclinicshavehigh OACcontrol. Our resultsalso supportt hose of previouslyp ublished randomised trials that INR self-management is at leaste quivalent to management by a specialisedanticoagulation clinic and seems to offermore accurate anticoagulation control than is obtained under routine care supervised by generalpractitioners (17, 27, 30) .
It is currentlytoo earlytoassess the effect of self-management on complications caused by OACt reatment,a nd the numberspresenteddid not indicateany difference betweentreatment groups. However, withimproved OACcontrol as an indirect parameter of areduced risk of thromboembolic and bleeding complications (32) , it can be expected that this benefitw ill be seen after termination of this trial. In addition, otherstudieshave convincingly shown thatq uality of life wass ignificantly improved in patients whoperformed self-management compared to patients advisedatspecialised clinics and in generalpractices as well (16, 33, 34) . Furthermore,self-management seemstobea cost-effectives trategyf or patients on long-termO AC therapy (35,3 6) . Analyseso nq uality of life and cost-effectivenessa re planned after termination of the study.
These preliminaryr esults suggest thats elf-management of OACissafe and feasible for elderlypatients willingtoparticipate in astructured training programme
